PBAC Approves XIFAXAN(R) (Rifaxamin á) 550 mg Cost Effectivene... - 24 May 2013 20:37

LONDON, May 24 /PRNewswire-AsiaNet/ -- Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy (HE) where other treatme...

  Handover of Five Provincial Vision Centres in Cambodia - 24 May 2013 13:00

Phnom Penh, May 24, 2013/ Medianet International-AsiaNet/-- Celebrations were in order recently in Phnom Penh, marking the official handover of five vision centres now established and operating in five previously underserved provinces of Cambodia. The handover ceremony marks the completion of th...

  Press Statement on Behalf of the Singh Family (The Former Shar... - 24 May 2013 00:57

GURGAON, India, May 24/PRNewswire-AsiaNet/ -- On 22 May 2013, Daiichi Sankyo released a press statement where, among other things, it was stated that it "believes that certain former shareholders of Ranbaxy concealed and misrepresented critical information concerning the US DOJ and ...

  Volcano Announces Preliminary Results from the ADVISE II Study... - 23 May 2013 19:37

SAN DIEGO and PARIS, May 23, 2013 /PRNewswire-AsiaNet/ -- Prospective, Multi-Center, Double-Blinded Study Confirms Prior Results in evaluating Volcano's iFR® (Instant Wave-Free Ratio™) Software Modality in a Large, Real-World Population Volcano Corporation (NASDAQ: ...

  New Clinical Data Presented at EuroPCR Demonstrates that TriGu... - 23 May 2013 04:15

PARIS and CAESAREA, Israel, May 23, 2013 /PR Newswire-Asianet/ -- - New clinical data presented from the DEFLECT-I study demonstrates that Keystone Heart's TriGuard(TM) Cerebral Protection Device reduces brain lesion volume during TAVR (Transcatheter Aortic Valve Replacement) procedures when compared to hist...

  Ranbaxy Announces Improved Business Standards and Quality Assu... - 22 May 2013 22:36

TOKYO, May 22 /Kyodo JBN-AsiaNet/ -- Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a subsidiary of Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo), announced on May 22 the actions that Ranbaxy has taken in recent years to address past conduct under prior management (http://...

  Grunenthal Presents a New Website for the Topical Treatment of... - 22 May 2013 21:44

AACHEN, Germany, May 22 /PRNewswire-AsiaNet/ -- Healthcare professionals who would like to know more about the topical treatment of postherpetic neuralgia (PHN) can now find useful information online. PHN is a chronic disabling pain condition with symptoms often described as burning, stabb...

  Research-based Pharmaceutical Industry Launches 'Do You Mind?'... - 21 May 2013 15:00

GENEVA, May 21, 2013/PRNewswire-AsiaNet/ -- - Campaign launched during World Health Assembly, where world's health ministers gather to address the large physical and economic costs of these disorders - Mental and neurological disorders (MNDs) affect 700 million peop...

  Industry insists Australian clinical trials are internationall... - 21 May 2013 11:35

SYDNEY, May 21,2012/ Medianet International - AsiaNet/ -- Industry claims that a report of Australian clinical trial costs is flawed. The report (https://www.kpmg.com/Global/en/IssuesAndInsights/ArticlesPublications/Documents/competitive-alternatives-special-report.pdf) on the global competitiveness ...

  Local CROs Unite for International Clinical Trials - 20 May 2013 17:12

SYDNEY, 20th May 2013 /MediaNet International - AsiaNet/-- Local CROs Unite for International Clinical Trials Global CROs are no longer the obvious choice for companies looking to run international clinical trials. The motion is towards locally based CROs that are connected internationally to drive dow...